Funding for this research was provided by:
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT PRO-2015.21)
Deutsche Forschungsgemeinschaft (DFG UNITE SFB-1389)
German Cancer Research Center (iMed)
Received: 7 June 2020
Accepted: 24 September 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: Access to NORDAN and SEER data was provided upon a request at the respective offices, Saarland data was publicly available, no additional approval was required.
: Not applicable.
: CS is now full-time employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. The company had no role in design, analysis or interpretation of the presented work.